APC

Recursion Provides Business Updates and Reports First Quarter 2024 Financial Results

Retrieved on: 
木曜日, 5月 9, 2024
AXIN1, Research, Partnership, Clostridioides difficile infection, Development, IND, DeepMind, NVIDIA, Biomarker, Drug discovery, Tempus, Pharmacokinetics, Map, ADME, Machine learning, Software, Appetite, Roche, APC, Infection, Neurofibromatosis type II, CCM, Transcriptome, Safety, Johnson & Johnson, Neuroscience, RNA, Artificial intelligence, FAP, Data science, Therapy, Translation, Chemistry, RBM39, Biology, Clinical trial, LILAC, NF2, University of Oxford, Recurrence, Computational biology, Hemangioma, Administration, Patient, Strategy, Trial of the century, Pharmaceutical industry

L(earnings) Call: Recursion will host a L(earnings) Call on May 9, 2024 at 5:00 pm Eastern Time / 3:00 pm Mountain Time.

Key Points: 
  • L(earnings) Call: Recursion will host a L(earnings) Call on May 9, 2024 at 5:00 pm Eastern Time / 3:00 pm Mountain Time.
  • Revenue: Total revenue was $13.8 million for the first quarter of 2024, compared to $12.1 million for the first quarter of 2023.
  • Research and Development Expenses: Research and development expenses were $67.6 million for the first quarter of 2024, compared to $46.7 million for the first quarter of 2023.
  • Net Loss: Net loss was $91.4 million for the first quarter of 2024, compared to a net loss of $65.3 million for the first quarter of 2023.

Venom’s BlackBook Zero 14 honoured with HPL best business laptop award

Retrieved on: 
木曜日, 5月 9, 2024
PC Gamer, HPL, Magnesium alloy, Glass, News, BlackBook, SMB, SOHO, Computer, TechRadar, WH, High, Intel Core, Facial recognition, APC, PC, DDR5, AC, SSD, Government, Windows 10, USB, PC World, Data-rate units, Video game

MELBOURNE, Australia, May 09, 2024 (GLOBE NEWSWIRE) -- Venom, manufacturer of performance orientated laptop computers has been recognised by HPL (High performance Laptops) for the Best Business laptop award.

Key Points: 
  • MELBOURNE, Australia, May 09, 2024 (GLOBE NEWSWIRE) -- Venom, manufacturer of performance orientated laptop computers has been recognised by HPL (High performance Laptops) for the Best Business laptop award.
  • The emphasis of the best business laptop award is on weight, battery life, screen quality and size, ports and connectivity, web conferencing, build quality, security and service level agreements.
  • Venom’s BlackBook Zero 14 Phantom G9 scored the highest in these categories overall thus winning the category award for best business laptop.
  • Factors contributing to the award are the BlackBook Zero 14 Phantom G9’s lightweight portable design and high-speed performance.

Immunocore reports first quarter financial results and provides a business update

Retrieved on: 
水曜日, 5月 8, 2024
CTA, Total, Research, HLA, IND, ASCO, Research and development, BMY, Annual report, Drug, Autoimmune disease, APC, HIV, Bristol Myers Squibb, TCR, Autoimmunity, Infection, PRAME, Treatment, EMA, GMP, Clinical trial, Investigational New Drug, Platinum, ImmTAC, Nivolumab, Security (finance), Form 10-Q, Half-life, Patient, Immune system, Pharmaceutical industry

& ROCKVILLE, Md., US, May 8, 2024) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”) , a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced its financial results for the first quarter ended March 31, 2024 and provided a business update.

Key Points: 
  • & ROCKVILLE, Md., US, May 8, 2024) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”) , a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced its financial results for the first quarter ended March 31, 2024 and provided a business update.
  • Net loss for the first quarter of 2024 was $24.4 million compared to a net loss of $19.4 million in the same period in 2023.
  • The first quarter basic and diluted loss per share was $0.49, compared to $0.40 for the first quarter of 2023.
  • This includes net cash proceeds of $390.2 million from the Company’s offering of convertible notes in February 2024.

Fuel Tech Reports 2024 First Quarter Financial Results

Retrieved on: 
火曜日, 5月 7, 2024
Utilities, Oil, Gas, Sustainability, Environment, Energy, Engineering, Green Technology, Manufacturing, CHEM, Investment, Weather, Aquaculture, DGI, Coal, Upcoming, APC, Adjustment, FUEL, Interest, Security (finance)

Fuel Tech, Inc. (NASDAQ: FTEK), a technology company providing advanced engineering for the optimization of combustion systems, emissions control, and water treatment in utility and industrial applications, today reported financial results for the first quarter (Q1 2024) ended March 31, 2024.

Key Points: 
  • Fuel Tech, Inc. (NASDAQ: FTEK), a technology company providing advanced engineering for the optimization of combustion systems, emissions control, and water treatment in utility and industrial applications, today reported financial results for the first quarter (Q1 2024) ended March 31, 2024.
  • We are currently pursuing additional FUEL CHEM opportunities at units that use coal and other fuel sources, which could provide incremental revenue contribution in the latter half of 2024.
  • Adjusted EBITDA loss was $(1.5) million in Q1 2024 compared to Adjusted EBITDA loss of $(0.6) million in Q1 2023.
  • Management will host a conference call on Wednesday, May 8, 2024 at 10:00 am ET / 9:00 am CT to discuss the results and business activities.

Elbit Systems Awarded Approximately $53 Million Contract to Supply Crossbow Unmanned Turreted Mortar Systems for a European Customer

Retrieved on: 
水曜日, 5月 8, 2024
General Dynamics Land Systems, Elbit Systems, Exhibition, Crossbow, APC, Iron, Telescopic sight

HAIFA, Israel, May 8, 2024 /PRNewswire/ -- Elbit Systems Ltd. (NASDAQ: ESLT) (TASE: ESLT) ("Elbit Systems" or the "Company") announced today that it was awarded a contract worth approximately $53 million to supply the Crossbow Unmanned Turreted 120mm Soft Recoil Mortar Systems to General Dynamics European Land Systems (GDELS) for the installation on Pandur 6x6 APC wheeled armored vehicle for a European customer.

Key Points: 
  • HAIFA, Israel, May 8, 2024 /PRNewswire/ -- Elbit Systems Ltd. (NASDAQ: ESLT) (TASE: ESLT) ("Elbit Systems" or the "Company") announced today that it was awarded a contract worth approximately $53 million to supply the Crossbow Unmanned Turreted 120mm Soft Recoil Mortar Systems to General Dynamics European Land Systems (GDELS) for the installation on Pandur 6x6 APC wheeled armored vehicle for a European customer.
  • This marks the first contract signed for the supply of the Crossbow since its unveiling at the DSEI exhibition in London in 2023.
  • Elbit Systems' Crossbow offers high protection and survivability for the mortar operator's crew and a short sensor-to-shooter circle, and is capable of shooting the first round in less than 30 seconds.
  • Yehuda (Udi) Vered, General Manager of Elbit Systems Land: "We are proud to receive the first order from a leading international costumer for our state-of-the-art Crossbow Unmanned Turreted Mortar System.

Venom's BlackBook Zero 14 Honored with HPL Best Business Laptop Award

Retrieved on: 
火曜日, 5月 7, 2024
PC Gamer, HPL, ABC, Magnesium alloy, Glass, News, BlackBook, SMB, SOHO, Computer, TechRadar, WH, High, Intel Core, Facial recognition, APC, PC, DDR5, AC, SSD, Government, Windows 10, USB, PC World, Data-rate units

MELBOURNE, Australia, May 7, 2024 /PRNewswire/ -- Venom, manufacturer of performance orientated laptop computers has been recognised by HPL (High performance Laptops) for the Best Business laptop award.

Key Points: 
  • MELBOURNE, Australia, May 7, 2024 /PRNewswire/ -- Venom, manufacturer of performance orientated laptop computers has been recognised by HPL (High performance Laptops) for the Best Business laptop award.
  • The emphasis of the best business laptop award is on weight, battery life, screen quality and size, ports and connectivity, web conferencing, build quality, security and service level agreements.
  • Venom's BlackBook Zero 14 Phantom G9 scored the highest in these categories overall thus winning the category award for best business laptop.
  • Factors contributing to the award are the BlackBook Zero 14 Phantom G9's lightweight portable design and high-speed performance.

Southeastern Grocers serves slice of summer with award-winning caramel apple pie and new frozen desserts

Retrieved on: 
金曜日, 5月 3, 2024
Retail, Supermarket, Food, Beverage, American Pie Council, Weather, Harveys Supermarkets, Winn-Dixie, American Pie, Love, Chocolate, Prestige, Taste, Butter, APC, Multimedia, Knowledge, Grocery store

Fresh off its victory at the American Pie Council’s National Championship, SEG proudly presents its acclaimed caramel apple pie alongside a delightful selection of its new frozen desserts.

Key Points: 
  • Fresh off its victory at the American Pie Council’s National Championship, SEG proudly presents its acclaimed caramel apple pie alongside a delightful selection of its new frozen desserts.
  • View the full release here: https://www.businesswire.com/news/home/20240503175375/en/
    Southeastern Grocers earns a piece of the pie with first-place award for its Own Brands caramel apple pie at American Pie Council’s National Championship.
  • (Photo: Business Wire)
    Crafted with care and culinary expertise, SEG’s caramel apple pie has become a favorite among customers and APC judges alike.
  • SEG’s caramel apple pie promises to be the highlight of any summer occasion, offering pure indulgence in every bite.

Sunbird Power IQ DCIM Monitoring Release 9.1 Available Now

Retrieved on: 
水曜日, 5月 1, 2024
Risk, G4, OS, 10K, Data center, APC, Anomaly, LDAP, N+1, Server Technology, DCIM

PISCATAWAY, N.J., May 1, 2024 /PRNewswire-PRWeb/ -- Sunbird Software, the global innovator in second-generation Data Center Infrastructure Management (DCIM) software, today announced the general availability of its latest Power IQ® release.

Key Points: 
  • PISCATAWAY, N.J., May 1, 2024 /PRNewswire-PRWeb/ -- Sunbird Software , the global innovator in second-generation Data Center Infrastructure Management (DCIM) software , today announced the general availability of its latest Power IQ® release.
  • "Deploying N+1 redundant power supplies are an important part of maintaining uptime and service availability," said Herman Chan, President, Sunbird Software.
  • Power IQ 9.1 includes a load shift detection feature that detects when the load shifts from one power supply on an IT device to another, which indicates a potential power supply issue that might impact redundancy.
  • Power IQ uses data from outlet-metered intelligent rack PDUs and a tunable AI algorithm to analyze a recent short-term window of power data for all IT devices and outlets.

Biotech Innovations Aim to Combat Soaring Cancer Diagnoses by 2050

Retrieved on: 
水曜日, 5月 1, 2024
FDA, Protein, APC, MRNA, Risk, Moderna, News, Death, Partnership, Skin cancer, Vaccine, ASCO, Spyglass, AACR, NK, Lung cancer, Colorectal cancer, CNBC, NMIBC, Infection, DPX, Messenger, CD8, Merck, NSCLC, RSV, Autumn, Safety, Triangle, Survival, American Cancer Society, DNA, Therapy, Medicine, Melanoma, Pembrolizumab, Biology, Peanut, Cancer, A9, Interview, Immunotherapy, DSM-IV codes, HSV, Habit, Zika virus, COVID-19, Disease, Patent, Patient, Society, Acquisition, Peptide, Antigen, Immune system

VANCOUVER, BC, May 1, 2024 /PRNewswire/ -- USA News Group – An alarming trend is happening around the world, where tens of millions of progressively younger people are being diagnosed with of cancer. A new report from the American Cancer Society projects that by 2050, the number of people diagnosed with cancer could rise by 77%. According to experts at last year's annual American Society of Clinical Oncology (ASCO) meeting, a little-known bacteria could be behind the rising rates of cancer in people under 40, along with pointing towards bad habits such as highly-processed diets and heavy alcohol use being potential catalysts. While five-year cancer survival rates are on an upward trend, the biotech sector is racing to meet these challenges head on with new treatments and safeguards against cancer, including recent developments from companies such as BioVaxys Technology Corp. (CSE: BIOV) (OTCQB: BVAXF), Moderna, Inc. (NASDAQ: MRNA), Boundless Bio, Inc. (NASDAQ: BOLD), ImmunityBio, Inc. (NASDAQ: IBRX), and MacroGenics, Inc. (NASDAQ: MGNX).

Key Points: 
  • A new report from the American Cancer Society projects that by 2050, the number of people diagnosed with cancer could rise by 77%.
  • "We now have massive opportunities in oncology, infectious disease, allergy desensitization, and autoimmune diseases," said Kenneth Kovan, President and Chief Operating Officer of BioVaxys.
  • The joint Moderna/Merck efforts are also testing the vaccine with Keytruda against other tumor types, including non-small cell lung cancer.
  • This shot is designed to train the immune system to recognize and attack specific mutations in cancer cells.

Biotech Innovations Aim to Combat Soaring Cancer Diagnoses by 2050

Retrieved on: 
水曜日, 5月 1, 2024
FDA, Protein, APC, MRNA, Risk, Moderna, News, Death, Partnership, Skin cancer, Vaccine, ASCO, Spyglass, AACR, NK, Lung cancer, Colorectal cancer, CNBC, NMIBC, Infection, DPX, Messenger, CD8, Merck, NSCLC, RSV, Autumn, Safety, Triangle, Survival, American Cancer Society, DNA, Therapy, Medicine, Melanoma, Pembrolizumab, Biology, Peanut, Cancer, A9, Interview, Immunotherapy, DSM-IV codes, HSV, Habit, Zika virus, COVID-19, Disease, Patent, Patient, Society, Acquisition, Peptide, Antigen, Immune system

VANCOUVER, BC, May 1, 2024 /PRNewswire/ -- USA News Group – An alarming trend is happening around the world, where tens of millions of progressively younger people are being diagnosed with of cancer. A new report from the American Cancer Society projects that by 2050, the number of people diagnosed with cancer could rise by 77%. According to experts at last year's annual American Society of Clinical Oncology (ASCO) meeting, a little-known bacteria could be behind the rising rates of cancer in people under 40, along with pointing towards bad habits such as highly-processed diets and heavy alcohol use being potential catalysts. While five-year cancer survival rates are on an upward trend, the biotech sector is racing to meet these challenges head on with new treatments and safeguards against cancer, including recent developments from companies such as BioVaxys Technology Corp. (CSE: BIOV) (OTCQB: BVAXF), Moderna, Inc. (NASDAQ: MRNA), Boundless Bio, Inc. (NASDAQ: BOLD), ImmunityBio, Inc. (NASDAQ: IBRX), and MacroGenics, Inc. (NASDAQ: MGNX).

Key Points: 
  • A new report from the American Cancer Society projects that by 2050, the number of people diagnosed with cancer could rise by 77%.
  • "We now have massive opportunities in oncology, infectious disease, allergy desensitization, and autoimmune diseases," said Kenneth Kovan, President and Chief Operating Officer of BioVaxys.
  • The joint Moderna/Merck efforts are also testing the vaccine with Keytruda against other tumor types, including non-small cell lung cancer.
  • This shot is designed to train the immune system to recognize and attack specific mutations in cancer cells.